ArticleOncoTargets and therapy2021

Anti-PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status.

Taichi Matsubara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.